Movectro Articles

Another blow for Merck KGaA as US FDA calls for more safety data on cladribine in MS

2 March 2011

Merck Serono pulls European application for oral MS drug Movectro; Sun withdraws topotecan

18 February 2011

Regulatory updates: AstraZeneca’s Brilinta; Merck KGaA’ cladribine

21 January 2011

European neurologists expect significant increases in the use of both Tysabri and Extavia in their multiple sclerosis patients

24 December 2010

Novartis gets Russian approval for oral MS drug Gilenya (fimgolimid)

13 September 2010

Merck Serono's oral MS drug cladribine gets second approval, in Australia

6 September 2010

Product marketing briefs from Merck & Co, Merck Serono, GW/Almirall, AstraZeneca and Roche

28 July 2010

A new era of multiple sclerosis therapies begins as oral drugs come to market

15 July 2010

Merck Serono gets first approval for oral MS drug, gaining Russian clearance for cladribine, with launch expected early 2011

12 July 2010

Neurologists eagerly await new oral treatment options for MS, such as EMD Serono's Movectro and Novartis' Gilenia

27 April 2010

Showing 1-10 of 10 articles

Go to beginningPrevious
  • 1
NextGo to end